ReviewCurrent heart failure reports2012
Pharmacogenetics in chronic heart failure: new developments and current challenges.
Review in Current heart failure reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.European journal of drug metabolism and pharmacokinetics · 2021Pooled it
- The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Clinical and translational science · 2025Article
- Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals.Clinical pharmacokinetics · 2024Article
- Article
- Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank.Circulation. Genomic and precision medicine · 2023Article
- Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure.Frontiers in cardiovascular medicine · 2022Article
- Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.Circulation. Heart failure · 2020Article
- Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure.Clinical and translational science · 2020Observational
- The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.British journal of clinical pharmacology · 2019Review
- Pharmacodynamic Evaluation of Shenfu Injection in Rats With Ischemic Heart Failure and Its Effect on Small Molecules Using Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging.Frontiers in pharmacology · 2019Article
- Race and Beta-Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self-Reported Race and Proportion of African Genetic Ancestry.Journal of the American Heart Association · 2018Observational
- Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients.JACC. Heart failure · 2017Article
- Genetics and heart failure: a concise guide for the clinician.Current cardiology reviews · 2015Review
- Article
- Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling.Pharmacogenomics and personalized medicine · 2014Review
- New advances in beta-blocker therapy in heart failure.Frontiers in physiology · 2013Review
- Contextualizing Genetics for Regional Heart Failure Care.Current cardiology reviewsReview
- Pharmacogenomics in heart failure: where are we now and how can we reach clinical application?Cardiology in reviewReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The individual patient responses to chronic heart failure (HF) pharmacotherapies are highly variable. This variability cannot be entirely explained by clinical characteristics, and genetic variation may play a role. Therefore, this review will summarize the background pharmacogenetic literature for major HF pharmacotherapy classes (ie, β-blockers, angiotensin-converting enzyme inhibitors, digoxin, and loop diuretics), evaluate recent advances in the HF pharmacogenetic literature in the context of previous findings, and discuss the challenges and conclusions for HF pharmacogenetic data and its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.